351 related articles for article (PubMed ID: 30383313)
1. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
[TBL] [Abstract][Full Text] [Related]
2. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
[TBL] [Abstract][Full Text] [Related]
3. Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.
Tsai M; Mukai K; Chinthrajah RS; Nadeau KC; Galli SJ
J Allergy Clin Immunol; 2020 Mar; 145(3):885-896.e6. PubMed ID: 31805311
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
[TBL] [Abstract][Full Text] [Related]
5. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.
Thyagarajan A; Jones SM; Calatroni A; Pons L; Kulis M; Woo CS; Kamalakannan M; Vickery BP; Scurlock AM; Wesley Burks A; Shreffler WG
Clin Exp Allergy; 2012 Aug; 42(8):1197-205. PubMed ID: 22805467
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the immunologic response to peanut during immunotherapy is often transient.
Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and immune regulation with peanut oral immunotherapy.
Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW
J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
[TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
[TBL] [Abstract][Full Text] [Related]
9. Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity.
Burton OT; Logsdon SL; Zhou JS; Medina-Tamayo J; Abdel-Gadir A; Noval Rivas M; Koleoglou KJ; Chatila TA; Schneider LC; Rachid R; Umetsu DT; Oettgen HC
J Allergy Clin Immunol; 2014 Dec; 134(6):1310-1317.e6. PubMed ID: 25042981
[TBL] [Abstract][Full Text] [Related]
10. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing IgG
Keswani T; LaHood NA; Marini-Rapoport O; Karmakar B; Andrieux L; Reese B; Sneed SL; Pedersen LC; Mueller GA; Patil SU
J Allergy Clin Immunol; 2024 Jun; 153(6):1611-1620.e7. PubMed ID: 38460677
[TBL] [Abstract][Full Text] [Related]
12. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
13. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
[TBL] [Abstract][Full Text] [Related]
14. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
15. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens.
Santos AF; James LK; Bahnson HT; Shamji MH; Couto-Francisco NC; Islam S; Houghton S; Clark AT; Stephens A; Turcanu V; Durham SR; Gould HJ; Lack G
J Allergy Clin Immunol; 2015 May; 135(5):1249-56. PubMed ID: 25670011
[TBL] [Abstract][Full Text] [Related]
16. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
17. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
[TBL] [Abstract][Full Text] [Related]
18. High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.
Kulis M; Yue X; Guo R; Zhang H; Orgel K; Ye P; Li Q; Liu Y; Kim E; Burks AW; Vickery BP
Clin Exp Allergy; 2019 Feb; 49(2):180-189. PubMed ID: 30126028
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.
Kulis MD; Smeekens JM; Burk C; Yue X; Guo R; Orgel KA; Ye P; Herlihy L; Hamilton D; Li Q; Keet C; Shreffler W; Vickery BP; Burks AW; Kim EH
J Allergy Clin Immunol; 2022 Nov; 150(5):1144-1153. PubMed ID: 35716952
[TBL] [Abstract][Full Text] [Related]
20. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
